# Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

> **NCT06227156** · PHASE2 · RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Disitamab Vedotin Injection

## Key facts

- **NCT ID:** NCT06227156
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-08
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06227156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06227156, "Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06227156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*